old agglutinins have been one of the banes of blood group serologists since pretransfusion testing protocols were first implemented. Cold autoagglutinins interfere with ABO/Rh typing tests, yield unwanted positive tests for unexpected antibodies, and may mask the presence of concomitant, clinically significant alloantibodies. Cold alloagglutinins, such as anti-M, -P 1 , or -Le a rarely cause accelerated destruction of mismatched red blood cells (RBCs), and it is not necessary to detect examples of these antibodies that only react below body temperatures.The extent to which cold agglutinins can interfere with the results of pretransfusion antibody detection and compatibility tests is evident from a study by Garratty 1 on the importance of anticomplement reagents in immunohematology. With a low-ionic-strength saline (LISS) method that included room temperature incubation and polyspecific (anti-IgG+ C3) antiglobulin serum, the rate of unwanted positive tests (due primarily to the detection of cold-reactive auto-and alloagglutinins) was on the order of 1.41 percent! Omitting the room temperature incubation phase and use of anti-IgG reduced the unwanted positive rate reduced to 0.1 percent.
AVOIDING COLD AGGLUTININSGiven these introductory comments, the proper handling of cold agglutinins in the transfusion service requires that pretransfusion antibody screening be performed utilizing methods that avoid their detection, namely: C 1. No reading for direct agglutination, including immediate-spin tests and direct reading after 37°C incubation. 2. No microscopic examination of tests. 3. Use of anti-IgG instead of polyspecific antiglobulin reagent.In these regards, polyethylene glycol or gel techniques 2,3 are ideal methods to use. Data supporting safety of the above recommendations are found in Trudeau and colleagues, 4 Laferriere and coworkers, 5 Judd and colleagues, [6][7][8] The one problem that can arise from omitting readings for direct agglutination when screening for unexpected antibodies is the occurrence of a positive immediate-spin cross-match when the screening tests are negative. In this situation, before implementing an electronic cross-match, our approach was to verify that blood of the correct ABO type had been selected and to crossmatch the units by the indirect anitglobulin test (IAT). If the units were compatible by IAT, they were released for transfusion. If not, an antibody identification study was initiated.